PepGen
Dr. Krieg currently serves as the Founder and Chief Scientific Officer (CSO) at Checkmate Pharmaceuticals, a clinical stage biotechnology company developing novel oligonucleotides for cancer immunotherapy. Prior to Checkmate, Dr. Krieg was CSO at Sarepta Therapeutics, Chief Executive Officer at RaNA Therapeutics, and CSO of Pfizer’s Oligonucleotide Therapeutics Unit. He brings more than 35 years of expertise in the oligonucleotide field, having served on the scientific advisory boards of several companies, driven multiple novel oligonucleotides from discovery to clinical development with the Coley Pharmaceutical Group, and published over 250 scientific papers.
This person is not in the org chart
PepGen
2 followers
Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.